Fears extra expense and paperwork caused by Brexit will make Britain unattractive to global drugmakers.

Delays caused by added bureaucracy following Brexit and other international situations such as the war in Ukraine are leading to shortage of medicines, with pharmacies scrambling to offer replacements so as not to keep their clients without the items they need.

Goods lorries entering Northern Ireland (NI) from Great Britain would have to complete a three-page certificate under EU plans to simplify post-Brexit trading arrangements.

Several large-scale smuggling incidents show that EU concerns over the operation of the Northern Ireland Protocol are not theoretical, it added.

A majority of MLAs in the Stormont Assembly have signed a joint letter to Prime Minister Boris Johnson stating their opposition to proposed legislation to amend the Northern Ireland Protocol.

Two in three British pharmacies are struggling daily to source painkillers, cancer drugs and other vital medicines, research shows, as the availability of pharmaceuticals becomes increasingly uncertain.

Brexit comes with uncertainty regarding the approval of medicines and medical devices, including software and technology. Regulatory hurdles could disrupt the approval of existing and new devices and technology.

A terminal cancer patient has been handed a hefty tax bill for her "miracle" lifesaving drugs, because of changes to how VAT is charged post-Brexit.

The issue stems from the outworkings of the NI Protocol, which means Northern Ireland remains covered by the EU’s pharmaceutical regulations.

An island nation must trade with its nearest mainland, whatever our new Brexit opportunities minister claims.

Hundreds of researchers and organisations across Europe have called for the rapid association of the UK and Switzerland to Horizon Europe.

The government has set out a plan to overhaul EU laws copied over after Brexit - a move it says will cut unnecessary "red tape" for businesses.

THE UK GOVERNMENT’S RESPONSE to Brexit and its failure to iron out key agreements after nearly a year outside the Single Market and Customs Union, are fuelling constant uncertainty over many aspects of health and social care in the UK, says a new report from the Nuffield Trust.

Our report published today looks at six key areas of health and social care that are being impacted by Brexit.

European Commission vice-president Maros Sefcovic is expected to announce proposed new legislation on Friday.

The UK’s medicines and devices regulator will stop work that “does not add value” and lose over 100 full time equivalent staff posts as part of its post-Brexit cost cutting drive, a leaked consultation document seen by The BMJ shows. / But experts warned that plans to streamline regulation to speed up the development and approval of new drugs for patients’ benefit carried potential safety risks.

European Commission Vice-President Maros Sefcovic urged London on Friday to conclude a deal to allow medicines to flow easily from Britain to Northern Ireland as well as other issues concerning trade to the British province.

The European Commission vice president has suggested the EU could act unilaterally to guarantee the supply of medicines from GB to Northern Ireland.

A fast-track visa route for Nobel prize laureates and other award-winners in science, engineering, the humanities and medicine has failed to attract any applicants.

NHS costs, food standards and intellectual property rights must be protected in any deal by the UK to join a major international trade agreement, a Lords committee has told ministers in a new report.

Britain must work with other countries to prevent friction on medicine rules post-Brexit to avoid being sidelined by the global drug industry, according to a report from the U.K.’s biggest pharmaceutical lobby group.

The well known logistics company, chaired by German billionaire Klaus-Michael Kühne, has been tasked with delivering “medicines and medical goods which are at risk of shortage” into the UK “within days”.

The government and its supporters are beginning to claim 'benefits' of being outside the European Union some of which were always available to EU member states or, in other cases, are not benefits at all.